CN110198945B - 用于制备噻唑烷二酮化合物及其盐的方法 - Google Patents

用于制备噻唑烷二酮化合物及其盐的方法 Download PDF

Info

Publication number
CN110198945B
CN110198945B CN201780084302.3A CN201780084302A CN110198945B CN 110198945 B CN110198945 B CN 110198945B CN 201780084302 A CN201780084302 A CN 201780084302A CN 110198945 B CN110198945 B CN 110198945B
Authority
CN
China
Prior art keywords
compound
solvent
reaction mixture
formula
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780084302.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110198945A (zh
Inventor
A·M·加西亚科拉佐
W·滕霍夫
J·N·科克
J·B·M·里温克尔
S·德维尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of CN110198945A publication Critical patent/CN110198945A/zh
Application granted granted Critical
Publication of CN110198945B publication Critical patent/CN110198945B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201780084302.3A 2016-12-23 2017-12-22 用于制备噻唑烷二酮化合物及其盐的方法 Active CN110198945B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382648 2016-12-23
EP16382648.0 2016-12-23
PCT/IB2017/058374 WO2018116281A1 (en) 2016-12-23 2017-12-22 Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Publications (2)

Publication Number Publication Date
CN110198945A CN110198945A (zh) 2019-09-03
CN110198945B true CN110198945B (zh) 2023-06-27

Family

ID=57799523

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780084302.3A Active CN110198945B (zh) 2016-12-23 2017-12-22 用于制备噻唑烷二酮化合物及其盐的方法

Country Status (19)

Country Link
US (2) US11124505B2 (enExample)
EP (1) EP3559010B1 (enExample)
JP (2) JP7294661B2 (enExample)
KR (1) KR102609373B1 (enExample)
CN (1) CN110198945B (enExample)
BR (1) BR112019012972B1 (enExample)
CA (1) CA3046744A1 (enExample)
CY (1) CY1125531T1 (enExample)
DK (1) DK3559010T3 (enExample)
ES (1) ES2926580T3 (enExample)
HR (1) HRP20221067T1 (enExample)
HU (1) HUE059604T2 (enExample)
IL (1) IL267557B (enExample)
LT (1) LT3559010T (enExample)
MX (1) MX379709B (enExample)
PL (1) PL3559010T3 (enExample)
PT (1) PT3559010T (enExample)
SI (1) SI3559010T1 (enExample)
WO (1) WO2018116281A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
HUE071482T2 (hu) 2018-06-06 2025-08-28 Minoryx Therapeutics S L (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra
MX2020013182A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.
JP2026500743A (ja) 2022-12-28 2026-01-08 ミノリックス セラピューティクス エセ.エレ. レリグリタゾンの最適投薬
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149550A1 (en) * 2007-04-27 2010-02-03 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2015150476A1 (en) * 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100249988B1 (ko) * 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
HUP0304096A2 (hu) 2003-12-19 2005-08-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
ATE447414T1 (de) 2005-02-16 2009-11-15 Micromet Ag Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren
EP2072519A4 (en) * 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
KR20150003766A (ko) * 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149550A1 (en) * 2007-04-27 2010-02-03 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2015150476A1 (en) * 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Studies on Antidiabetic Agents.XII.1) Synthesis and Activity of the Metabolites of (±)-5-[p-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione(Pioglitazone);Takashi SOHDA et al.;《Chem.Pharm.Bull》;19951215;图1,Chart 2 *
Synthesis and Biological Activity of Metabolites of the Antidiabetic,Antihyperglycemic Agent Pioglitazone;Steven P. Tanis et al.;《J. Med. Chem.》;19961220;图2,Scheme 1 *

Also Published As

Publication number Publication date
IL267557B (en) 2021-10-31
US20190389852A1 (en) 2019-12-26
PT3559010T (pt) 2022-09-01
HUE059604T2 (hu) 2022-11-28
ES2926580T3 (es) 2022-10-27
WO2018116281A1 (en) 2018-06-28
KR102609373B1 (ko) 2023-12-01
HRP20221067T1 (hr) 2022-11-25
US20220204496A1 (en) 2022-06-30
IL267557A (en) 2019-08-29
JP2023052918A (ja) 2023-04-12
KR20190100300A (ko) 2019-08-28
DK3559010T3 (da) 2022-08-15
EP3559010A1 (en) 2019-10-30
PL3559010T3 (pl) 2022-11-21
CN110198945A (zh) 2019-09-03
BR112019012972A2 (pt) 2019-12-31
SI3559010T1 (sl) 2022-10-28
US11731963B2 (en) 2023-08-22
MX379709B (es) 2025-03-11
US11124505B2 (en) 2021-09-21
CY1125531T1 (el) 2026-02-25
LT3559010T (lt) 2022-10-10
MX2019007327A (es) 2019-09-02
JP7294661B2 (ja) 2023-06-20
CA3046744A1 (en) 2018-06-28
EP3559010B1 (en) 2022-06-08
BR112019012972B1 (pt) 2023-04-18
JP2020502228A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
JP7294661B2 (ja) 5-[[4-[2-[5-(1-ヒドロキシエチル)-2-ピリジニル]エトキシ]フェニル]メチル]-2,4-チアゾリジンジオンおよびその塩を調製するためのプロセス
TW202024032A (zh) 用於製備6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸甲酯之方法
JP2000516933A (ja) 極めて脂肪親和性のカンプトテシン誘導体
JP2025183283A (ja) 選択的エストロゲン受容体分解剤の調製のためのプロセス
CN1918168B (zh) 制备3-o-保护吗啡酮和3-o-保护吗啡酮二烯醇羧酸酯的方法
US9434740B2 (en) Taxane compounds, compositions and methods
HK40013289A (en) Process for preparing thiazolidinedione compounds and salts thereof
HK40013289B (en) Process for preparing thiazolidinedione compounds and salts thereof
CN102656177B (zh) 螺酮缩醇衍生物的制备方法
HK40014767A (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
HK40014767B (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
CN117534663A (zh) 稠合的三并环衍生物及其在药学上的应用
US9309259B2 (en) Process for ixabepilone, and intermediates thereof
US20240199629A1 (en) Processes for the preparation of selective estrogen receptor degraders
WO2014108011A1 (zh) 恩替卡韦中间体及其制备方法
CN106588565A (zh) 一种羟基邻位为卤原子取代的手性仲烯丙醇的合成方法
HK1119160B (en) Methods for making 3-o protected morphinones and 3-o-protected morphinone dienol carboxylates

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013289

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant